Figure 2.
Mechanism of action of durvalumab: normal immune response (A); tumor immune invasion (B); and immune response restoration (C).
Abbreviations: MHC, major histocompatibility complex; APC, antigen presenting cell; TCR, T cell receptor; PD1, programmed death receptor; CTLA4, cytotoxic T-lymphocyte-associated protein 4.